MX2022012678A - Compuestos y metodos para modular el corte y empalme. - Google Patents

Compuestos y metodos para modular el corte y empalme.

Info

Publication number
MX2022012678A
MX2022012678A MX2022012678A MX2022012678A MX2022012678A MX 2022012678 A MX2022012678 A MX 2022012678A MX 2022012678 A MX2022012678 A MX 2022012678A MX 2022012678 A MX2022012678 A MX 2022012678A MX 2022012678 A MX2022012678 A MX 2022012678A
Authority
MX
Mexico
Prior art keywords
splicing
methods
compounds
modulate
cutting
Prior art date
Application number
MX2022012678A
Other languages
English (en)
Spanish (es)
Inventor
Allen T Hopper
Peter Smith
Dominic Reynolds
Sudeep Prajapati
Serge Leger
Michael W Seiler
Anant A Agrawal
Frederic Vaillancourt
Olivier Soueidan
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of MX2022012678A publication Critical patent/MX2022012678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Replacement Of Web Rolls (AREA)
MX2022012678A 2020-04-08 2021-04-08 Compuestos y metodos para modular el corte y empalme. MX2022012678A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007331P 2020-04-08 2020-04-08
US202063044318P 2020-06-25 2020-06-25
US202063072922P 2020-08-31 2020-08-31
US202063126494P 2020-12-16 2020-12-16
PCT/US2021/026481 WO2021207554A1 (en) 2020-04-08 2021-04-08 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
MX2022012678A true MX2022012678A (es) 2023-01-11

Family

ID=75690721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012678A MX2022012678A (es) 2020-04-08 2021-04-08 Compuestos y metodos para modular el corte y empalme.

Country Status (15)

Country Link
US (2) US20230167093A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132646A1 (cg-RX-API-DMAC7.html)
JP (1) JP7879597B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167298A (cg-RX-API-DMAC7.html)
CN (1) CN115551593A (cg-RX-API-DMAC7.html)
AU (1) AU2021253587A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174353A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002780A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015925A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220566A (cg-RX-API-DMAC7.html)
IL (1) IL297137A (cg-RX-API-DMAC7.html)
MX (1) MX2022012678A (cg-RX-API-DMAC7.html)
TW (1) TWI912305B (cg-RX-API-DMAC7.html)
WO (2) WO2021207554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
US20250332173A1 (en) * 2021-10-13 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
JP2024541481A (ja) * 2021-11-24 2024-11-08 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
US20250326748A1 (en) * 2022-01-05 2025-10-23 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN116377059B (zh) * 2023-04-28 2026-05-15 华中科技大学同济医学院附属协和医院 Luc7l2在诊断和治疗急性肾损伤中的用途
WO2024259017A1 (en) * 2023-06-12 2024-12-19 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CN120388720B (zh) * 2024-09-18 2026-02-17 大连医科大学附属第二医院 基于uqcc2与mettl3的计算机辅助筛选药物的方法、系统和设备

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309765A3 (en) * 1987-09-30 1990-09-26 Fisons Corporation 1(2h)-phthalazinones as cytoprotective agents
DE60010448T2 (de) * 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20090069300A1 (en) * 2007-09-12 2009-03-12 Wyeth Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
UA111579C2 (uk) * 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
HK1219421A1 (zh) * 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
WO2017050865A1 (en) * 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
RS63116B1 (sr) * 2016-05-06 2022-05-31 Shanghai De Novo Pharmatech Co Ltd Derivat benzazepina, postupak za dobijanje, farmaceutska kompozicija i njegova upotreba
US10913730B2 (en) * 2016-10-10 2021-02-09 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as Mer inhibitors
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
US11590167B2 (en) * 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
WO2018133865A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
CN108658990B (zh) * 2017-03-31 2021-03-23 南京科技职业学院 一类新型咪唑并[1,5-a]吡嗪类布鲁顿激酶抑制剂
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
CN109721597B (zh) * 2017-10-30 2021-05-14 上海迪诺医药科技有限公司 吡啶并氮杂卓衍生物、其药物组合物及应用
WO2019094312A1 (en) * 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
KR20230024328A (ko) * 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도

Also Published As

Publication number Publication date
CR20220566A (es) 2023-01-23
CO2022015925A2 (es) 2024-09-09
US20230167093A1 (en) 2023-06-01
EP4132646A1 (en) 2023-02-15
US20230159496A1 (en) 2023-05-25
CL2022002780A1 (es) 2023-04-28
TW202208344A (zh) 2022-03-01
CA3174353A1 (en) 2021-10-14
BR112022020423A2 (pt) 2022-11-29
WO2021207532A1 (en) 2021-10-14
AU2021253587A1 (en) 2022-12-01
KR20220167298A (ko) 2022-12-20
JP2023520916A (ja) 2023-05-22
CN115551593A (zh) 2022-12-30
IL297137A (en) 2022-12-01
TWI912305B (zh) 2026-01-21
JP7879597B2 (ja) 2026-06-24
WO2021207554A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
MX2022012676A (es) Compuestos y metodos para modular el empalme.
CO2022013832A2 (es) Amidas heterocíclicas y su uso para modular el empalme
BR112022017089A2 (pt) Derivados de piridazina para modular o splicing de ácido nucleico
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2021001461A1 (es) Moduladores de trex1
CO2022015925A2 (es) Compuestos y métodos para modular el corte y empalme
MX2022010681A (es) Compuestos y metodos para modular el empalme.
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
PE20091419A1 (es) Derivados acidos de carboxicicloalquilamino como moduladores de los receptores de esfingosina-1-fosfato (s1p)
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CO2018001264A2 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos
UY40387A (es) Derivados de pirimidiniloxi benceno como herbicidas
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
UY36651A (es) Compuestos antiestrogénicos
AR104731A1 (es) Benzamidas sustituidas y métodos para utilizarlas
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
UY37551A (es) Activador de nrf2
MX2024002554A (es) Compuestos y metodos para modular el empalme.
MX2024002558A (es) Compuestos y métodos para modular splicing.
MX389097B (es) Estabilizador altamente eficaz.
MX2025015073A (es) Compuestos y metodos para modular el empalme